The Future of Clinical Trials in Idiopathic Pulmonary Fibrosis

There was an urgent need for better treatments for idiopathic pulmonary fibrosis. The two treatments approved by the U.S. Food and Drug Administration, nintetinib and perfenedone, low disease progression, but do not stop or reverse lung fibrosis. Doctors Anna Potolanchik, Luca Rucheldi, and Fernando Martinez have an accompanying editorial titled, The Future of Clinical Trials in Idiopathic Pulmonary Fibrosis.